Description

Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor[1][2][3][4].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–Cancer-Kinase/protease–C24H29N5O7—-[1]Chen YC, et al. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002;45(8):1624-1632.|[2]Chen Z, et al. Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)]. Protein Pept Lett. 2009;16(9):1074-1080.|[3]Fazzi R, et al. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk Res. 2002;26(1):19-27.|[4]Battolla B, et al. The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit. 2011;17(1):SC1-SC5.–105250-85-9–499.52–99.69–OC(C=C1)=CC=C1C[C@H](N)C(NCC(N[C@H](C(NCC(NCC(O)=O)=O)=O)CC2=CC=CC=C2)=O)=O–Others–DMSO : 8.93 mg/mL (ultrasonic;warming;heat to 60°C)–Src—-Protein Tyrosine Kinase/RTK–Peptides